Abstract :Abstract
Dengue is a mosquito-borne, rapidly rising viral infection with around 400 million cases per year. The toll of this high number may be attributed to the lack of availability of vaccine and specific treatment. Therefore, the development of novel antivirals is of vital importance. All the 4 serotypes of Dengue virus (DENV) could actively infect the same population with different immune responses. Thus, various studies are focused towards finding potent antiviral therapeutics to target various DENV serotypes, and further inhibit cross-reactivity among similar viruses and antibody dependent enhancement of infection. Antiviral therapeutics targeting potential restriction sites during different stages of virus life cycle were studied. Several of them were conducted using small compounds like a tetracycline derivatives, polysaccharides, lectins, or monoclonal antibodies as antiviral therapeutics for DENV infection. In this paper, we are elucidating potential antiviral therapeutics as well as immune-therapies against DENV infection.